Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial

Despite current therapies, patients with vascular disease remain at high risk for major adverse cardiovascular events. Low-density lipoprotein cholesterol is a well-established modifiable cardiovascular risk factor. Evolocumab is a fully human monoclonal antibody inhibitor of proprotein convertase s...

Full description

Saved in:

Bibliographic Details
Published in:	The American heart journal Vol. 173; pp. 94 - 101
Main Authors:	Sabatine, Marc S., Giugliano, Robert P., Keech, Anthony, Honarpour, Narimon, Wang, Huei, Liu, Thomas, Wasserman, Scott M., Scott, Robert, Sever, Peter S., Pedersen, Terje R.
Format:	Journal Article
Language:	English
Published:	United States Elsevier Inc 01.03.2016 Elsevier Limited
Subjects:	Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal, Humanized Australia - epidemiology Cardiovascular Cardiovascular disease Cardiovascular diseases Cardiovascular Diseases - blood Cardiovascular Diseases - epidemiology Cardiovascular Diseases - prevention & control Cholesterol, VLDL - blood Cholesterol, VLDL - drug effects Clinical trials Dose-Response Relationship, Drug Double-Blind Method Drug Administration Schedule Drug Therapy, Combination Female Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage Incidence Injections, Subcutaneous Lipids Lipoproteins, LDL - blood Lipoproteins, LDL - drug effects Low density lipoprotein Male Morbidity Norway - epidemiology Proprotein Convertase 9 Proprotein Convertases - antagonists & inhibitors Risk Assessment Risk Factors Serine Endopeptidases Statins Survival Rate - trends Treatment Outcome United Kingdom - epidemiology United States - epidemiology Vascular diseases United Kingdom Australia Norway United States
ISSN:	0002-8703, 1097-6744
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!